Elixirr International plc (ELIX.L) — Research Note

Executive summary

Elixirr is a UK-headquartered "challenger consultancy" that has compounded revenue at ~38% CAGR since its 2020 AIM IPO, grew to £111.3m in FY24 and is set to clear £149m in FY25 (subject to audit), with Adjusted EBITDA margins consistently at 28-30% 2026-01 trading update; 2025-04 final results. The trajectory across the period covered is one of disciplined organic growth (17% in H1 25) layered with nine acquisitions, of which iOLAP (data/AI, US$125m max consideration), Hypothesis (US research/insights) and Kvadrant (Nordic commercial transformation) materially expanded both capability and geographic reach. The single most important valuation point today is that the April 2026 secondary placing cleared £12m at 750p in an oversubscribed book, suggesting the market is comfortable paying ~13x forward earnings for a Rule-of-50 business — a fair but not generous level that leaves limited margin of safety relative to the user's "don't overpay" pillar.

Fair value estimate

Range: 700p – 950p per share, mid ~825p → implied market cap £350m – £475m (mid £413m).

Methodology — forward P/E and EV/EBITDA cross-check:

• FY25 adjusted diluted EPS implied at ~55-58p (H1 25 was 29.0p + acquisitions; FY24 was 43.1p) 2025-09 interims; 2025-04 final.
• FY26 EPS plausibly ~65-72p with full-year contributions from TRC and Kvadrant.
• Applying 12-15x FY26E EPS gives 780p–1,080p; weighting on the more conservative end gives a 700-950p range.
• EV/EBITDA cross-check: FY25E Adj EBITDA ~£42m. EV of £400m (mid mcap £413m + ~£24m net debt less leases, less placing proceeds) implies ~9.5x — in line with quality professional-services peers.

vs. latest disclosed market cap £368.2m: implied upside of ~12-15% to mid case. The 750p placing price effectively benchmarks where institutional demand cleared in April 2026.

Sector context

ICB classification (Industrials / Industrial Goods & Services) is technically correct but materially misleading — this is a professional-services business that behaves more like a specialist IT-services / strategy-consulting peer. Quality: above average (Rule of 50, 28-30% margins, high client retention, partner-equity culture). Growth: substantially above sector (35% reported, 17% organic in H1 25 vs ~3-8% for the wider consulting market) 2025-09 interims. Leverage: in line / below (0.6x net debt / EBITDA, fortress-light). Listed comparables include Accenture (NYSE: ACN), AlphaSights peers, and on AIM, Kin & Carta (pre-take-private) and historically MPAC / RPS. Closest direct peer is probably Accenture for valuation reference and Capita / IBM Consulting for industry dynamics, though Elixirr operates at a much higher growth rate and margin profile than either.

Investment thesis (3 bullets)

1. AI-adjacent execution play with proven cross-sell mechanics. The iOLAP (now Elixirr Digital), Hypothesis and Responsum (Elixirr AI) acquisitions give Elixirr the capability stack to win larger AI/data transformation mandates — H1 25 cross-sell revenue grew 78% to £14.7m, and partners are delivering AI/data work to a Fortune 500 client base 2025-09 interims. This positions Elixirr as a beneficiary of corporate AI implementation spend, even if the value capture is not as concentrated as a pure-play picks-and-shovels vendor.
2. Consistent, candid execution against Rule of 40/50. Every year since AIM IPO the firm has exceeded Rule of 40 (revenue growth + EBITDA margin > 40); FY24 and FY25 cleared Rule of 50 2026-01 trading update. Partner revenue per head continues to grow (£2.3m H1 25 vs £2.1m H1 24), Gold clients (>£1m) up to 34 from 27, and FY25 ended with record contracted revenue — operational momentum is real and broad-based 2025-09 interims; 2026-01.
3. Fortress balance sheet with disciplined M&A. Year-end FY25 net debt of £24.1m (excl. leases) was ~£7m better than consensus, achieved despite eight post-IPO acquisitions including the iOLAP earn-out and the £18m Kvadrant deal in Jan 2026 2026-01; 2026-02 acquisition. The Group has consistently used the EBT and cash to minimise dilution; recent acquisitions priced at 4-8x EV/EBITDA, well below ELIX's own multiple, creating immediate accretion.

Key risks (3 bullets)

1. Consulting is inherently cyclical and people-dependent. The prospectus explicitly flags partner retention, client mandate wins and US financial-services concentration as principal risks 2025-09 interims, risk section. A downturn would see consulting spend contract first; the H1 25 partner ramp (Stern, Troy, TRC partners) raises near-term partner-cost intensity if utilisation slips.
2. Earn-out and contingent consideration overhang. As of 30 June 2025, £3.3m current and £1.1m non-current contingent consideration was recognised, and TRC could trigger up to US$68m further deferred consideration in cash or shares through 2028. This creates equity-issuance risk and complicates near-term EPS visibility 2025-09 interims, note 9; 2025-09 TRC acquisition.
3. AI exposure is incidental, not structural. Elixirr sells consulting services to clients adopting AI; it is not embedded in the AI supply chain. If management's own commentary about AI-driven efficiency in back-office work is correct industry-wide, junior-grade consulting hours are themselves at some risk of substitution over a 5-10 year horizon — a structural rather than cyclical headwind [inferred from disclosed Group AI strategy].

Operating leverage

Limited. Cost of sales was £75.5m on £111.3m of FY24 revenue (~68%), reflecting that the dominant cost is consultant compensation, which scales close to linearly with revenue 2025-04 final results. Gross margin sits at 33-34% and has been stable across the period; the meaningful operating-leverage signal is in central overheads (administrative expenses grew only 28% on 30% revenue growth in FY24, and 47% on 35% revenue growth in H1 25 — slightly less than revenue) 2025-09 interims. Incremental margin economics: at scale, an additional £1 of revenue plausibly drops 30-35p to gross profit and 25-30p to Adjusted EBITDA, broadly in line with the current 30% margin — i.e. revenue beats expand profit only modestly. A 10-20% revenue surprise above plan would lift operating profit by maybe 12-25%, not the 50-100%+ that platforms or capacity-constrained businesses deliver. The Croatian Centre of Excellence and South African Data & AI Academy do introduce some operating leverage on the delivery side, but this is a relatively modest fixed-cost lever rather than a step-change. Conclusion: this is structurally a moderate-leverage professional-services business; the "long tail of outcomes" pillar is not well-served.

Value-trap signals

None identified. The opposite is true: revenue accelerating, margins expanding, balance sheet strengthening, dividend growing (FY24 17.8p, FY25 interim 7.6p +21%), index inclusion catalyst (FTSE 250 ambition for 2026), and clean accounting with thorough APM disclosure. The Cape Point Guest Lodges/Wine and Aviation E LLP related-party transactions are de minimis (<£75k combined annually) and disclosed appropriately. Watch items rather than red flags: rising loans-to-shareholders balance (£9.1m at H1 25) representing partner share-purchase financing, and growing share-based payment cost (£2.2m H1 25 vs £1.1m H1 24).

Earnings vs. expectations

• FY22: Adjusted EBITDA ~£20.5m delivered against "above £20m" guidance and margin in middle of 27-29% range. Beat 2023-02 trading update; 2023-04 final.
• FY23: revenue £85.9m vs guidance £85-90m, Adj EBITDA £25.4m. In line / slight miss on top of range 2024-01 trading update.
• H1 24 / FY24: revenue £111.3m above £108-111m guidance, Adj EBITDA margin 28% (mid of 27-29%), Adj EBITDA £31.2m vs market £31m. Beat 2025-02 trading update.
• H1 25 / FY25: revenue £71.4m H1 (+35%); FY25 revenue "expected to meet or exceed" £149m consensus, margin to meet/exceed 28.1-29.2% range, year-end net debt £7m favourable to expectations. Beat 2026-01 trading update.

Pattern: A clean run of beats or in-line prints since IPO, with management guidance set conservatively and consistently exceeded. No profit warnings; reported numbers reconcile cleanly to APMs.

Conviction

Conviction: 4 (high).

Anchors: (i) thorough, consistent IFRS disclosure with reconciliations of all APMs, including share-based payments, contingent consideration finance costs and M&A items, making valuation modelling tractable; (ii) the April 2026 placing at 750p provides an explicit market-clearing reference point at a specific moment in time, giving the fair-value range a real anchor; (iii) five-year track record of meeting or beating guidance reduces the variance of the central case.

Caveats: (i) the iOLAP and TRC earn-outs create FY26-28 EPS-dilution uncertainty depending on cash vs share settlement choices; (ii) FY26 will include first-time-full contributions from Kvadrant and TRC alongside continued organic growth, making the Y/Y bridge harder to forecast precisely without broker model access.

Driver scoring rationale

• AI beneficiary (55): Consulting on AI implementation is a beneficiary category, but value capture is indirect — Elixirr sells partner days to clients building AI, rather than owning AI infrastructure, models or data assets. The Responsum/iOLAP/Hypothesis stack puts them in a credible position in the value chain but it is not a pure picks-and-shovels play. Above middle of medium band.
• Operating leverage (40): Professional services with ~68% variable cost ratio. Some central-overhead leverage but no platform or capacity dynamic that would deliver multi-bagger profit on revenue surprise.
• Earnings surprise trend (78): Consistent beats or in-line prints across nine reporting periods since IPO; H1 25 a clear beat.
• Cyclicality (55): Diversified, but consulting demand is cyclical in absolute terms. Moderate.
• Moat (45): Brand, partner relationships and integration playbook are real but not structural; competitors can replicate the model.
• Leverage (25): 0.6x net debt / EBITDA, with strong cash generation; low risk of distress.
• Earnings quality (70): Cash conversion solid (FCF £28.1m FY24 on £31.2m EBITDA); reconciliations transparent; some adjusting items (M&A, share-based payments) are recurring in nature.
• Management quality (78): Founder-led, candid disclosure, programmatic M&A executed without shareholder dilution since 2021, equity participation in 70%+ of acquired teams.
• Growth momentum (82): 35% reported / 17% organic in H1 25, accelerating from prior periods; record contracted revenue entering FY26.

Overall score rationale

530 / 1000: Genuinely high-quality business, but only partial fit with the strategy. AI exposure is real but indirect (~35% weighting on AI receiver = moderate contribution); operating leverage is structurally limited (~25% weighting on op leverage = clear miss); valuation is fair but not cheap (~25% weighting = neutral, slight upside in central case); downside protection is strong (~15% weighting = positive). The lack of structural operating leverage is the binding constraint — this stock will not deliver "incremental revenue drops disproportionately to profit" in the way the user wants.